|
|
Home > Healthcare > Biotechnology > Cell/Tissue Engineering
Stem Cell Markets
|
|
- 1. Overview
- 1.1 Statement of Report
- 1.2 Scope of the Report
- 1.3 Methodology
- 1.4 Executive Summary
- 2. Biology of Stem Cells
- 2.1 Scope of this Chapter
- 2.2 Basic Properties of Stem Cells and Their Classification
- 2.3 Differentiation of Stem Cells
- 2.3.1 Neural and Neuronal Differentiation
- 2.3.2 Cardiomyogenic Differentiation of ESCs
- 2.3.3 Differentiation of Mesenchymal Stem/Progenitor Cells
- 2.4 Self-Renewal of Stem Cells
- 2.5 Dedifferentiation and Nuclear Reprogramming
- 2.6 Functional Proliferation of Adult Mature Cells
- 2.7 Nanog Promotes Transfer of Pluripotency After Cell Fusion
- 2.8 MicroRNAs in Stem Cell Development
- 2.9 Stem Cell Therapy
- 3. Market Analysis of the Stem Cell Space
- 3.1 Scope of this Chapter
- 3.2 Overall Market Opportunity and Segmentation of the Total Stem Cell Marketplace
- 3.3 Potential Stem Cell Commercial Applications
- 3.3.1 Cord Blood Stem Cells and Cord Blood Stem Cell Banking: Current Market Environment and Opportunity
- 3.4 Results of Primary Market Survey to Characterize Qualitative and Quantitative Trends in the Stem Cells Space
- 3.4.1 Characteristics of the Respondent Pool
- 3.4.2 Utilization of the Different Classes of Stem Cells
- 3.4.3 Quantitative Metrics of the Stem Cell Research Marketplace: Number of Experiments Performed in Research
- 3.4.4 Evolution of Research Activities with Different Types of Stem Cells:
- Current Usage Trends and Usage in 12 to 18 Months
- 3.4.5 Types of Stem Cell Research Activities Performed by the End-User Community
- 3.4.6 Challenges Facing Stem Cell Researchers
- 3.4.7 Market Drivers and Research Questions Being Addressed in the Stem Cell Space
- 3.4.8 Summary of Challenges and Opportunities in the Stem Cell Space Based on TriMark’s Analysis
- 3.4.9 Unmet Product Needs in the Stem Cell Research Space and Licensing/IP Constraints
- 3.5 Competitive Landscape of the Stem Cell Marketplace
- 3.5.1 SWOT Analysis of the Major Stem Cell Market Segments
- 3.6 Market Size and Forecasts
- 4. Worldwide Landscape of Stem Cell Research
- 4.1 Scope of this Chapter
- 4.2 Global Embryonic Stem Cell Research
- 4.2.1 Top Research Institutions Worldwide in the Stem Cells Space and Global “Hot Spots” for Research and Therapeutics
- 4.3 Stem Cell Research in the U.S.
- 4.3.1 Proposition 71 in the State of California
- 4.4 Intellectual Property (IP) Landscape Surrounding Stem Cells
- 4.5 Who Will Finance Stem Cell Research?
- 4.5.1 U.S. Government Policy on Stem Cell Research
- 4.5.2 Current Federal Policy
- 4.5.2.1 Moral Issues Affecting Pre-Obama Federal Policy
- 4.5.2.2 Significance and Requirements for Federal Funding
- 4.5.2.3 Draft Guidelines for the new NIH stem cell funding policy
- 4.5.3 International Law
- 4.5.3.1 Australia
- 4.5.3.2 U.K.
- 4.5.3.3 Canada
- 4.5.3.4 China
- 4.5.3.5 Germany
- 4.5.3.6 Switzerland
- 4.5.3.7 Japan
- 4.5.3.8 Israel
- 4.5.3.9 Singapore
- 4.5.4 Technological and Economical Disadvantages for the U.S.
- 5. Therapeutic Areas and Research Programs in the Stem Cell Space
- 5.1 Scope of this Chapter
- 5.2 Therapeutic and Other Markets Addressed by Stem Cells
- 5.2.1 Hematopoietic Stem Cells (HSCs)
- 5.2.2 Stem Cell Therapeutics for Cardiac and Ischemic Diseases
- 5.2.3 Stem Cell Therapeutics for Type I Diabetes
- 5.2.4 Stem Cell Therapeutics for Orthopedic Diseases
- 5.2.5 Stem Cell Therapeutics for Neurological Diseases
- 5.3 Off-the-Shelf Stem Cells Being Developed
- 6. Company Profiles
- 6.1 Aastrom Biosciences
- 6.2 Advanced Cell Technology
- 6.3 BioE
- 6.4 Bioheart
- 6.5 Cryo-Cell International
- 6.6 ES Cell International
- 6.7 Gamida Cell
- 6.8 GenVec
- 6.9 Geron
- 6.10 NeuroGeneration
- 6.11 Osiris Therapeutics
- 6.12 Pluristem Therapeutics
- 6.13 ReNeuron
- 6.14 StemCells, Inc.
- 6.15 Titan Pharmaceuticals
- 6.16 ViaCell (now PerkinElmer)
- Appendix 1. Glossary of Terms in Stem Cell Biology
- INDEX OF FIGURES
- Figure 2.1: Derivation of Embryonic Stem Cells (ESCs) from the Inner Cell Mass of Blastocysts
- Figure 2.2: Classification of Stem Cells: Embryonic Stem Cells Versus Adult Stem Cells
- Figure 2.3: Somatic Cell Nuclear Transfer (SCNT)
- Figure 3.1: Segmentation of the Stem Cell Marketplace Based Upon Commercial Offerings—Products and Services
- Figure 3.2: Geographical Breakout of Stem Cell End-User Survey Respondents
- Figure 3.3: Affiliation (Pharma, Biotech, Academic/University) of Stem Cell End-User Survey Respondents
- Figure 3.4: Survey Respondents That Are Studying Stem Cells or Using Stem Cells in Their Research
- Figure 3.5: Length of Time Survey Respondent Pool Has Been Studying Stem Cells or Using Stem Cells in Its Research Activities
- Figure 3.6: Utilization/Research with Different Stem Cell Types
- Figure 3.7: Number of Experiments Involving Stem Cells Conducted Per Week
- Figure 3.8: Differences with Respect to Usage of Stem Cell Types
- Figure 3.9: Research Dollars Spent Monthly on Research/Studies with Different Stem Cell Types
- Figure 3.10: Growth of Research Spending in Various Segments of the Stem Cells Space (Defined by Stem Cell Type)
- Figure 3.11: Growth in End-User Utilization of Various Stem Cell Types
- Figure 3.12: Breakout of the Stem Cell Research Market: Current Research Efforts with Different Types of Stem Cells
- Figure 3.13: Breakout of the Stem Cell Research Market: Research Efforts with Different Types of Stem Cells in 12 to 18 Months
- Figure 3.14: Broad Classification of Research Activities Being Performed with Stem Cells by Researchers
- Figure 3.15: Current End-User Utilization Category for Adult Stem Cells (ASCs)
- Figure 3.16: Current End-User Utilization Category for Human Embryonic Stem Cells (hESCs)
- Figure 3.17: Current End-User Utilization Category for Human Cord Blood Stem Cells
- Figure 3.18: Current End-User Utilization Category for Animal Stem Cells
- Figure 3.19: Current End-User Utilization Category for Cancer Stem Cells
- Figure 3.20: Challenges in the Study or Utilization of Adult Stem Cells (ASCs)
- Figure 3.21: Challenges in the Study or Utilization of Human Embryonic Stem Cells (hESCs)
- Figure 3.22: Challenges in the Study or Utilization of Human Cord Blood Stem Cells
- Figure 3.23: Challenges in the Study or Utilization of Animal Stem Cells
- Figure 3.24: Challenges in the Study or Utilization of Cancer Stem Cells
- Figure 3.25: Top Unmet Needs in Commercial Products in the Stem Cell Research Space
- Figure 3.26: U.S. Stem Cell Therapy Market Sales, 2005-2016
- Figure 4.1: Stem Cell Research Worldwide
- INDEX OF TABLES
- Table 2.1: The Different Types of Stem Cells and Their Properties
- Table 2.2: Adult Stem Cell (ASC) Differentiation Properties
- Table 3.1: Characteristics of Different Stem Cell Types and Associated Market Opportunities
- Table 3.2: Segmentation of the Stem Cell Market by Type/Lineage of Stem Cells
- Table 3.3: Selected Cord Blood Banks in the U.S.
- Table 3.4: Selected Companies in the Cord Blood Stem Cell Technology and
- Therapeutics Development Space
- Table 3.5: Breakout of the Stem Cell Research Market: Current Research Efforts with Different Types of Stem Cells
- Table 3.6: Breakout of the Stem Cell Research Market: Research Efforts with
- Different Types of Stem Cells in 12 to 18 Months
- Table 3.7: Market Share of Companies/Institutions Offering Different Stem Cells to Researchers
- Table 3.8: Market Share of Companies/Institutions Offering Reagents for Stem Cell Research
- Table 3.9: The U.S. Stem Cell Therapy Market Forecast, 2005-2016
- Table 4.1: Major Milestones in Stem Cell Research and Associated Timeline, 1981-2009
- Table 4.2: Selected Stem Cell Hot Spots Worldwide Administering Non-FDA Approved Stem Cell Therapeutic Regimens
- Table 4.3: NIH Funding of Stem Cell Research in the U.S., 2004-2009
- Table 4.4: Snapshot of the Current Key Stem Cell Patents
- Table 5.1: Estimate of Potential Market Opportunity for Stem Cell-based Therapeutics
- Table 5.2: Autologous Versus Allogeneic Cell Therapy
- Table 5.3: Diseases Treated with HSC Transplantation Today
- Table 5.4: HSC Sources and Their Properties
- Table 5.5: Stem Cell Therapeutics for Hematological Diseases in Development
- Table 5.6: Stem Cell-based Therapeutics for Cardiac and Ischemic Diseases in Development
- Table 5.7: Stem Cell-based Therapeutics for Vascular Diseases in Development
- Table 5.8: Stem Cell Therapeutics for Type I Diabetes in Development
- Table 5.9: Stem Cell Therapeutics for Orthopedic Disease in Development
- Table 5.10: Stem Cell Therapeutics for Neurological Disease in Development
- Table 5.11: Segmentation of the Allogeneic Cell Therapy Market
|
Similar Products
• Regenerative Medicines: Bone and Joint Applications
Published Oct 2009 by BCC Research
• Growth Factors (Blood And Tissue)
Published Oct 2008 by Global Industry Analysts
• Advances in Replacement Organs and Tissue Engineering (Technical Insights)
Published Sep 2008 by Frost & Sullivan
• Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development
Published Mar 2008 by Kalorama Information
• Tissue Engineering and Cell Transplantation: Technologies, Opportunities, and Evolving Markets in the U.S.
Published Jul 2007 by Medtech Insight
• Stem Cell - Analysis and Market Forecasts, 2006-2016
Published Mar 2007 by RRY Publications
• Tissue Engineering & Stem Cell Technology Report 2007
Published Feb 2007 by Visiongain
• Hitting the Bull's-Eye with Your Eyes Closed: The Stem Cell Magic Bullet
Published Dec 2006 by IDC
• New Options for Treating Neurological Disease: Stem Cell Therapy
Published Dec 2006 by Decision Resources
|
|
|
|
0 items
